Pfizer is rolling the dice again on an oral obesity pill.The pharmaceutical giant signed an exclusive global license agreement with YaoPharma, a subsidiary of China’s Fosun Pharma.The deal involves YP05002, an oral small-molecule GLP-1 agonist, with a $150 million upfront payment plus up to $1.935 billion in milestone rewards.This marks…
JPMorgan stock (NYSE: JPM) tanked nearly 5% on Tuesday after the bank’s consumer banking chief warned that 2026 expenses…
Global markets opened on Wednesday on a cautious note as investors balanced major corporate developments with heightened macroeconomic uncertainty.…
Nintendo’s latest share slump is drawing attention to a wider shift in the tech supply chain, as rising memory…
The US shale sector is anticipating a new round of M&A-driven consolidation among small- and medium-sized producers. This trend is…
The Indian subcontinent, long favoured by multinationals for its vast consumer market, is now drawing a fresh wave of…
Nu Quantum has secured fresh investor attention as momentum in quantum networking rises across the global technology and energy…
India’s equity markets are seeing renewed enthusiasm for technology businesses that specialise in serving smaller cities, and Meesho Ltd.’s…
Rolls-Royce share price has held steady in the past few days, moving from a low of 1,020p on November…